Document is current
Any future updates will be listed below
-
Authors
Ranjan, Kishu
Rajendran, Barani Kumar
Deen, Imad Ud
Costantini, Adrien
de Rodas, Miguel Lopez
Desai, Shruti S.
Scallo, Frankie
Gianino, Nicole
Ferrone, Soldano
Schalper, Kurt A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R03CA219603, R03CA219603)
National Institutes of Health, United States (R37CA245154)
Yale SPORE in Lung Cancer (P50CA196530)
Merck Sharp and Dohme United Kingdom
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 23 February 2025
First Online: 17 March 2025
Declarations
:
: All the studies were conducted in accordance with recognized ethical guidelines (e.g., Declaration of Helsinki, CIOMS, Belmont Report, U.S. Common Rule) and tissue and clinical information were used after approval from the Yale Human Investigation Committee protocols 9505008219, 1412015109, 1608018220, and 1603017333, which approved the patient consent forms or waiver of consent.
: K. A. Schalper reports fees for consultant services, advisor or speaker from Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, EMD Serono, Takeda, Torque/Repertoire Therapeutics, CSRlife, Agenus, Genmab, OnCusp, Sanofi, Parthenon Therapeutics, Bristol-Myers Squibb, Roche, Molecular Templates, Dynamicure, DAiNA, NetxPoint Therapeutics, Merck, PeerView, PER and Forefront Collaborative. K. A. Schalper reports research funding from, Takeda, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Boehringer-Ingelheim, NextPoint Therapeutics and Roche.
